Speaker Profile

M.D., Ph.D., Medical Director, MolDX; Chief Medical Officer, Palmetto GBA

Dr. Bien-Willner is the Medical Director of the MolDX program at Palmetto GBA, a Medicare Administrative Contractor (MAC). MolDX seeks to understand the molecular testing landscape to implement payer controls, coverage, and to set policy for affiliated MACs, which currently cover 28 states. He is a leader in the Precision Medicine space and practices as a Board-certified Anatomic Pathologist and Molecular Genetic Pathologist. Throughout his career, he has been active in research, development, and advancement of molecular diagnostic services, specifically next generation sequencing. He has worked closely with clinicians to develop clear clinical diagnostic and treatment pathways directing Precision Medicine programs for community cancer centers. Dr. Bien-Willner received his MD and PhD degrees from Baylor College of Medicine, with a PhD in Human Molecular Genetics. He completed his residency, fellowship, and attained a faculty appointment at Washington University in St. Louis prior to leadership roles in laboratory and biotech companies before joining Palmetto GBA.

 Session Abstract – PMWC 2020 Silicon Valley

Reimbursement of diagnostic tests are a core component of Precision Medicine. Convincing payers of the medical necessity of a new diagnostic test can be challenging. Timely access for patients with the most compelling unmet needs requires the reimbursement environment transition to a transparent value-based model using fit-for-purpose levels of evidence.